Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2
- 18 February 2021
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 73 (3) , 962-965
Abstract
Background Amantadine is a drug that can help in the prevention of SARS-CoV-2 symptomatology, as has been demonstrated in observational clinical studies. Methods We searched in the PubMed database Clinical Studies of coronavirus-infected patients who have been treated with amantadine in a preventive manner as well as patients with Parkinson’s disease. Results Four clinical studies were found in which relatives of patients with COVID-19 had been prescribed the use of amantadine in a preventive manner to avoid the symptoms caused by the coronavirus. Conclusion Amantadine is a drug that can be prescribed as a prophylactic that prevents symptomatology caused by SARS-CoV-2 coronavirus.Keywords
This publication has 19 references indexed in Scilit:
- Amantadine Treatment for People with COVID-19Archives of Medical Research, 2020
- Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairmentMultiple Sclerosis and Related Disorders, 2020
- Amantadine as a drug to mitigate the effects of COVID-19Medical Hypotheses, 2020
- Does amantadine have a protective effect against COVID-19?Neurologia i Neurochirurgia Polska, 2020
- Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatmentInternational Journal of Antimicrobial Agents, 2020
- Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19Annals of Clinical Microbiology and Antimicrobials, 2020
- What can Parkinson’s disease teach us about COVID-19?Neurologia i Neurochirurgia Polska, 2020
- WHO Declares COVID-19 a Pandemic2020
- Potentially repurposing adamantanes for COVID‐19Journal of Medical Virology, 2020
- Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory virusesAntiviral Research, 2016